New Hampshire 2023 Regular Session

New Hampshire Senate Bill SB34

Introduced
1/5/23  
Refer
1/5/23  
Report Pass
1/18/23  
Engrossed
3/20/23  
Refer
3/20/23  
Report Pass
4/26/23  
Enrolled
6/20/23  
Chaptered
7/11/23  

Caption

Relative to the controlled drug prescription health and safety program.

Impact

The proposed changes will require prescribers to complete continuing education on pain management and addiction as part of the licensing process, thereby elevating the standards for those issuing prescriptions for controlled substances. By enforcing stricter controls, SB 34 aims to reduce instances of misuse and abuse of prescription medications. Furthermore, it structurally modifies how data from the prescription health and safety program can be used and shared, improving the ability of the department of health to analyze, evaluate, and support statewide public health initiatives regarding substance use disorders.

Summary

Senate Bill 34, also known as the Act Relative to the Controlled Drug Prescription Health and Safety Program, introduces several technical amendments to improve the Missouri prescription monitoring system. The primary aim of the bill is to enhance how opioid prescriptions are monitored, with specific emphasis on the management of chronic pain and ensuring that prescribers are adequately trained in pain management and addiction. These adjustments are intended to provide a framework that enables healthcare providers to navigate the complexities of prescribing controlled substances effectively while safeguarding patient health and safety.

Sentiment

Overall, the sentiment around SB 34 appears to be supportive, particularly among health professionals and policymakers focused on addressing the opioid crisis in the state. The necessary measures are viewed as proactive steps towards responsible prescribing practices. However, concerns were raised regarding the implications of stricter regulation and the capacity for prescribers to manage increased responsibilities around documentation and compliance, which some believe could impede patient care.

Contention

Notable points of contention surrounding SB 34 include debates on the balance between necessary oversight and the potential for overregulation. While the bill is largely endorsed by public health advocates, some practitioners fear that the added requirements may complicate their ability to provide timely care. The bill has sparked discussions about the need for continuous assessment of regulations to ensure they are beneficial rather than burdensome, especially in emergency situations where immediate access to pain management is necessary.

Companion Bills

No companion bills found.

Similar Bills

MN SF5329

Prescription drugs price increases and reporting requirements provisions

NJ A2809

Permits import of Canadian prescription drugs.

MS SB2012

Mississippi Health Care Cost Transparency Act; enact.

MN HF3054

Prescription drug transparency provisions modified.

MN SF3294

Prescription drug transparency provisions modifications

MN SF2108

Provisions modification for federal compliance for over-the-counter hearing aids

MN HF2038

Federal compliance for over-the-counter hearing aid provisions changed.

CT HB07159

An Act Addressing Opioid Use.